Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) have been assigned a consensus recommendation of “Moderate Buy” from the fourteen ratings firms that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, twelve have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $102.5833.

Several brokerages have issued reports on MIRM. Stifel Nicolaus lifted their target price on shares of Mirum Pharmaceuticals from $92.00 to $98.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. Cantor Fitzgerald reissued an “overweight” rating and set a $130.00 price target on shares of Mirum Pharmaceuticals in a research report on Monday, December 8th. Morgan Stanley upped their price objective on Mirum Pharmaceuticals from $81.00 to $95.00 and gave the company an “overweight” rating in a research report on Tuesday, December 9th. TD Cowen reiterated a “buy” rating on shares of Mirum Pharmaceuticals in a research note on Monday, January 12th. Finally, Citigroup restated an “outperform” rating on shares of Mirum Pharmaceuticals in a research note on Friday, December 19th.

Key Headlines Impacting Mirum Pharmaceuticals

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Baird updated Mirum’s valuation after the company reported a beat-and-raise on results, a development that supports upside and follows recent analyst price-target increases. Baird updates Mirum valuation
• Positive Sentiment: Multiple brokerages have raised targets/ratings in recent weeks (Morgan Stanley, HC Wainwright, Stifel, Robert W. Baird and others), reflecting confidence in revenue growth and the company’s lead product (maralixibat). These upgrades help underpin higher consensus price targets. MarketBeat analyst notes
• Neutral Sentiment: Company fundamentals: Mirum is a late-stage biopharma focused on rare cholestatic liver diseases; recent quarter showed strong revenue growth and an EPS beat, but the company remains loss-making on GAAP metrics and carries leverage. This context supports analyst optimism but also ongoing execution risk. Company profile and results
• Neutral Sentiment: Institutional activity shows modest position changes by funds (small buys/sells), not a clear directional institutional shift. Institutional holdings
• Negative Sentiment: Significant insider selling: several senior executives sold shares on Jan. 22 — CEO Christopher Peetz (7,098 shares), COO Peter Radovich (2,382), CFO Eric Bjerkholt (1,421), SVP Jolanda Howe (926) and insider Joanne Quan (multiple recent sales). The block of insider sales (each at ~\$93.33) reduces insider ownership and is likely weighing on sentiment and the stock today. Insider trades alert

Mirum Pharmaceuticals Stock Down 1.8%

MIRM stock opened at $94.29 on Monday. The business has a 50 day moving average of $77.33 and a 200 day moving average of $70.64. The firm has a market cap of $4.85 billion, a PE ratio of -109.64 and a beta of 0.48. Mirum Pharmaceuticals has a twelve month low of $36.88 and a twelve month high of $96.84. The company has a quick ratio of 3.16, a current ratio of 3.31 and a debt-to-equity ratio of 1.06.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its earnings results on Tuesday, November 4th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.15. The firm had revenue of $133.01 million for the quarter, compared to analysts’ expectations of $130.11 million. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.The company’s quarterly revenue was up 47.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.30) earnings per share. On average, research analysts forecast that Mirum Pharmaceuticals will post -1.43 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Eric Bjerkholt sold 1,421 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $93.33, for a total value of $132,621.93. Following the completion of the sale, the chief financial officer directly owned 42,127 shares in the company, valued at $3,931,712.91. The trade was a 3.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Jolanda Howe sold 926 shares of the business’s stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $93.33, for a total transaction of $86,423.58. Following the transaction, the senior vice president directly owned 3,042 shares of the company’s stock, valued at $283,909.86. The trade was a 23.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 20,560 shares of company stock worth $1,897,717 in the last quarter. Insiders own 14.36% of the company’s stock.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. MCF Advisors LLC lifted its holdings in shares of Mirum Pharmaceuticals by 76.4% during the 3rd quarter. MCF Advisors LLC now owns 427 shares of the company’s stock valued at $31,000 after buying an additional 185 shares during the period. Quantbot Technologies LP purchased a new stake in Mirum Pharmaceuticals during the third quarter valued at $33,000. Comerica Bank lifted its holdings in Mirum Pharmaceuticals by 45.1% in the first quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after acquiring an additional 278 shares during the period. Quarry LP purchased a new position in Mirum Pharmaceuticals in the third quarter worth about $41,000. Finally, CWM LLC grew its stake in shares of Mirum Pharmaceuticals by 30.8% during the 3rd quarter. CWM LLC now owns 683 shares of the company’s stock valued at $50,000 after purchasing an additional 161 shares during the period.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.